GeneTether Therapeutics, Inc. (RIZE) AI Stock Analysis

• Market Cap: $2.27M
• Dividend Yield: N/A
• Average Volume (3M): 5.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.38
• Revenue Growth: N/A
• EPS Growth: -20.10%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 75,744,675
• 10 Day Avg. Volume: 10,770
• 30 Day Avg. Volume: 5,895
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ―

GeneTether Therapeutics, Inc. is financially stable with strong equity and no debt, which is crucial for a pre-revenue biotech firm. Despite the lack of revenue, the positive technical indicators suggest short-term bullish sentiment. However, the negative P/E ratio and absence of dividends indicate inherent risks associated with its valuation.

GeneTether Therapeutics, Inc. Business Overview & Revenue Model

Company Description

GeneTether Therapeutics, Inc. (RIZE) is a biotechnology company focused on developing innovative gene editing technologies to treat genetic disorders. The company operates in the biotech and healthcare sectors, primarily working on pioneering approaches to enhance the precision and efficiency of gene editing. GeneTether Therapeutics aims to address unmet medical needs by creating therapies that can correct genetic mutations at their source.

How the Company Makes Money

GeneTether Therapeutics, Inc. generates revenue through a combination of strategic partnerships, licensing agreements, and research collaborations with pharmaceutical companies and academic institutions. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on sales of products developed using their technology. Additionally, the company may also receive funding from grants and government programs designed to support innovative biotech research.

GeneTether Therapeutics, Inc. Financial Statement Overview

Summary

GeneTether Therapeutics, Inc. shows strong equity with no debt, providing financial stability in the short term. However, the company faces challenges with revenue generation and cash flow sustainability, typical of pre-revenue biotech firms.

Income Statement

GeneTether Therapeutics, Inc. has consistently reported zero revenue over the years, which is common in early-stage biotech firms focusing on research and development. However, the company has significantly reduced its net losses in recent years, indicating some control over operational expenses. Without revenue or profit, margins and growth rates are not applicable.

Balance Sheet

The company has strong equity with no debt, showing financial stability and low risk related to leverage. The equity ratio is high, reflecting a solid capital structure buoyed by stockholders' equity. Despite this, the absence of revenue generation poses a risk to long-term sustainability if external funding is not secured.

Cash Flow

GeneTether has managed its cash well, maintaining positive cash balances and reducing free cash flow deficits. However, the operating cash flow remains negative, indicating reliance on financing activities for sustainability. The lack of revenue and positive net income highlights potential cash flow challenges.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	0.00	0.00	0.00	0.00	0.00
	EBIT
-750.25K	-747.28K	-1.72M	-1.64M	-71.96K	-86.23K
	EBITDA
-750.03K	0.00	-1.71M	-1.64M	-71.96K	-509.00
	Net Income Common Stockholders
-696.96K	-688.36K	-1.71M	-1.64M	-73.97K	-86.74K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.25M	1.36M	1.80M	179.83K	45.39K	10.11K
	Total Assets
1.25M	1.41M	1.94M	370.45K	45.39K	13.12K
	Total Debt
0.00	0.00	0.00	0.00	122.13K	20.28K
	Net Debt
-1.25M	-1.36M	-1.80M	-179.83K	76.75K	10.16K
	Total Liabilities
54.86K	38.59K	87.42K	213.22K	123.16K	21.39K
	Stockholders Equity
1.20M	1.37M	1.86M	157.22K	-77.78K	-8.27K
Cash Flow		Free Cash Flow
-393.18K	-464.86K	-1.18M	-740.26K	-69.06K	-95.46K
	Operating Cash Flow
-393.18K	-464.86K	-1.18M	-740.26K	-69.06K	-95.46K
	Investing Cash Flow
0.00	0.00	0.00	0.00	0.00	0.00
	Financing Cash Flow
0.00	0.00	3.00M	874.71K	104.33K	80.00K

GeneTether Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:RIZE, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.06, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 45.52 is Neutral, neither overbought nor oversold. The STOCH value of 10.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:RIZE.

GeneTether Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OGI	69 Neutral	$235.64M	16.91	4.76%	―	26.93%	―
RIZE	54 Neutral	$2.27M	―	-44.38%	―	―	-20.10%
Sector *	53 Neutral	$5.22B	3.33	-44.36%	7.55%	16.78%	-0.12%